This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Glucagon receptor
From Proteopedia
This page, as it appeared on June 20, 2016, was featured in this article in the journal Biochemistry and Molecular Biology Education.
Glucagon G protein-coupled receptor
Class B GPCRsG protein-coupled receptors (GPCRs) are the largest class of integral membrane proteins. GPCRs are divided into five families; the rhodopsin family (class A), the secretin family (class B), the glutamate family (class C), the frizzled/taste family (class F), and the adhesion family.[1] Roughly 5% of the human genome encodes g protein-coupled receptors, which are responsible for the transduction of endogenous signals and the instigation of cellular responses.[1] All GPCRs contain a similar seven α-helical transmembrane domain that once bound to its ligand, undergoes a conformational change and tranduces a signal to coupled, heterotrimeric G proteins. The initiation of intracellular signal pathways occur in response to stimuli such as light, Ca2+, amino acids, nucleotides, odorants, peptides, and other proteins, and accomplishes many interesting physiological roles. [1] The human glucagon receptor (GCGR) is one of 15 secretin-like, or Class B, G-protein coupled receptors (GPCRs). Like other GPCRs, it has a helical domain and a globular N-terminus (ECD). Class B GPCRs contain 15 distinct receptors for peptide hormones and generate their signal pathway through the activation of adenylate cyclase (AC) which increases the intracellular concentration of cAMP, inositol phosphate, and calcium levels. [3] These secondary messengers are essential elements of intracellular signal cascades for human diseases including type II diabetes mellitus, osteoporosis, obesity, cancer, neurological degeneration, cardiovascular diseases, headaches, and psychiatric disorders; making their regulation through drug targeting of particular interest as disease targets. [4] Structural approaches to the development of agonists and antagonists have however been hampered by the lack of accurate Class B TMD visualizations. Recent crystal structures of corticoptropin-releasing factor receptor 1 (PDB: 4K5Y) and human glucagon receptor (PDB: 4L6R) provide a comparison to more well-studied class A GPCRs. [5][2] Structures of Class A vs. Class B GPCRsClass A and class B glucagon receptors share less than fifteen percent sequence homology, but both share a 7TM domain.[5] Comparison of the helices to that of the helices showed that the general orientation and positioning of the alpha helices are conserved through both classes. Detailed structural alignments of the two GPCR subclasses revealed deviations in the transmembrane region.[2] For instance, the N-terminal end of in class B GCGR is longer than any known class A GPCR structure and stretches three supplementary helical turns above the extracellular (EC) membrane boundary. This region is referred to as the . The stalk is involved in glucagon binding and helps in defining the orientation of the ECD with respect to the 7TM domain.[2] Also specific to class B GPCRs, a Gly residue at position 393 induces a ; this bend is stabilized by the hydrophobic interaction between the . One of the most distinguishable characteristics of the class B 7TM is the of 25 degrees and its length compared to that of , which is much shorter. This helical tilt results from Glu 406 in helix VIII that is fully conserved in secretin-like receptors and forms two interhelical with conserved residues Arg 173 and Arg 346.[2] Despite these differences, a vital region that is conserved in both class B and class A receptors is the disulfide bond between in extracellular loop two (ECL2). This bond stabilizes the receptors entire 7TM fold. Lastly, the locations of the extracellular tips for class B glucagon receptors allow for a much wider and deeper ligand-binding pocket than any of the class A GPCRs.[2] While interfacial interactions are not unique to class B receptors, part of the interface between helices VI, V, and III includes a Class B-specific hydrogen bond between Asn 318 of Helix V and Leu 242 of Helix III.[2] How These Structures Lead to Function Structurally, the 7TM and its signature seven helical structure is involved in signaling via coupling to heterotrimeric G proteins that activate adenylate cyclase to increase the levels of intracellular cyclic AMP. Additionally, this coupling increases levels of IP3 and intracellular calcium levels.[2] The wider and deeper ligand-binding pocket of class B GPCRs allows for a vast array of molecules to be bound that in turn allow for numerous functions activated by peptide receptors. [7] The conformation and orientation of the 7TM and the ECD regions dictate the functionality of the class B G protein-coupled receptor, which has an open and closed conformation of the GCGR (Figure 2). The open conformation is when glucagon can bind to GCGR; in the closed conformation binding does not occur.[7] Glucagon Receptor (GCGR)The glucagon class B GPCR (GCGR) is involved in glucose homeostasis through the binding of the signal peptide glucagon. Glucagon is released from pancreatic α-cells when blood glucose levels fall after a period of fasting or several hours following intake of dietary carbohydrates.[8] Once the peptide hormone is released, it binds to GCGR, a 485 amino acid protein found in the liver, kidney, intestinal smooth muscle, brain, and adipose tissues. [9] Upon binding, signaling is initiated to heterotrimeric G-proteins containing Gαs. [10] GCGR can regulate additional signal pathways, including G-proteins of the Gαi family through the adoption of differing receptor conformations. [11] Glucagon's main role is the regulation of blood glucose levels.[8] Glucagon lowers the concentration of fructose 2,6-bisphosphate, which is an allosteric inhibitor of the gluconeogenic enzyme fructose 1,6-bisphosphotase and activates phosphofructose kinase 1, which increases glucose levels via glycolysis.[8] Glucagon is also a regulator of the production of cholesterol, which is an energetically intensive process. When energy resources are low, downregulation of cholesterol production begins with glucagon binding to GCGR, which stimulates the phosphorylation of HMG-CoA.[8] HMG-CoA is inactivated by phosphorylation and moderates cholesterol production to conserve energy.[8] Glucagon also takes part in fatty acid mobilization by affecting levels of adipose tissue in the organism. Activation of GCGR by glucagon initiates triacylglycerol breakdown and the phosphorylation of perilipin and lipases via cAMP signal pathways.[8] This allows the body to export fatty acids to the liver and other crucial tissues for energy use and makes more glucose available for use in brain functioning.[8] GCGR-Specific TraitsHelix I Stalk RegionThe tip of Helix I extends above the cell membrane into the extracellular space creating a . This region is longer than any other class of GPCR and extends three α-helical turns above the plane of the membrane. The stalk is proposed to capture the glucagon peptide and to facilitate insertion of the glucagon peptide into the 7tm.[2] Intracellular Helix VIIIThe GCGR also contains an intracellular Helix VIII that is comprised of roughly 20 amino acids at the C-terminal end. This helix tilts approximately 25 degrees away from the membrane - the corresponding position in class A receptors are turned toward the membrane.[2] This helix is completely conserved in class B structures. Binding Pocket Other Unique Structural FeaturesAn important interface stabilization interaction between Helices I and VII occurs between Ser 152 of Helix I and Ser 390 of Helix VII. Due to their close proximity to one another, they form an important which stabilizes the structure of GCGR. Mutations to the homologous residues Ser 135 and Ser 392 alters receptor signaling in glucagon-like peptide-1 receptor (GLP1R). Glucagon BindingThe large, soluble N-terminal extracellular domains (ECD) of GCGR provide initial ligand selectivity with the deep, ligand pocket of the TMD providing secondary recognition.[9] The residues in the binding pocket that are in direct contact with the glucagon molecule are polar or are hydrophobic. The N-terminus of glucagon binds partly with the ECD while the rest of glucagon binds deep into the binding pocket. The amino acids at the N-terminus of the class B 7TM have the ability to form hydrogen bonds and ionic interactions, which can be seen in the amino acid sequence of glucagon (Figure 5). [12]  GCGR regions providing binding affinity for glucagon include the α-helical structure of the . The α-helical structure of the stalk interacts directly with glucagon, as it extends nearly three helical turns above the membrane. When the alpha helix of the stalk is disrupted, the affinity of glucagon for GCGR decreases with an to proline substitution having significantly lower affinity for glucagon.[2] The high affinity conformation of GCGR is the open conformation, when glucagon can bind (Figure 2). The disulfide bond between serves to hold the helices in the proper orientation for binding and stabilizes the open conformation. Additionally, the salt bridges between hold the open conformation together for higher affinity. [7] Mutagenesis and photo cross-linking studies determined essential, conserved residues in glucagon and have been in red.[2] Glucagon residues His 1, Gln 3, Phe 6, and Tyr 10 are critical to successful binding interaction with the GCGR while others are important for structural rigidity. The n-terminus of glucagon (Figure 5) leads to a protuberance that fits into the deep, interior cavity of the GCGR 7TMD (Figure 3) where four residues reside that play strong roles in ligand binding affinity. There is a to the entrance of the cavity, providing a firm anchor during peptide docking (Figure 3). Glucagon Signaling PathwayGlucagon binds to the open conformation of GCGR on the plasma membrane. Glucagon binding to GCGR induces a conformational change in GCGR. This conformation change induces the active state of the protein (Figure 2). The active state of the protein exchanges a guanosine diphosphate (GDP) for guanosine triphosphate (GTP) that is bound to the alpha subunit. With the GTP in place, the activated alpha subunit dissociates from the heterotrimeric G protein'sbeta and gamma subunits. Following dissociation, the alpha subunit can activate adenylate cyclase. Activated adenylate cyclase, catalyzes the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). cAMP then serves as a secondary messenger to activate, through allosteric binding, cAMP dependent protein kinase A (PKA). PKA activates via phosphorylation the phosphorylase b kinase. The phosphorylase b kinase phosphorylates glycogen phosphorylase b to convert to the active form, phosphorylase a. Phosphorylase a finally catalyzes the release of glucose-1-phosphate into the bloodstream from glycogen polymers (Figure 6).  Clinical relevanceBecause GCGR can interact with multiple types of G protein subfamilies, discovering small molecule inhibitors could lead to a wide range of focused therapies.[13] Blocking conformations that favor interaction with specific G proteins could allow the knockdown of targeted signal pathways. For example, GCGR interacts with inhibitory Gαi proteins that antagonize cAMP production.[13] Finding an agonist for this pathway could be used to treat diabetes mellitus. Current attempts to target the GCGR have however been relatively unsuccessful. Small molecule modulators have been reported with enhanced pharmaceutical regulation, but the progress has been modest.[14] Encouraging results have recently come from Eli Lilly and Company who have been testing a small molecule antagonist of the GCGR (LY2409021) in phase two trials, providing hope for more specific control of diabetes mellitus.[14] In addition to diabetes mellitus, future development of signal bias modulators promise to provide focused therapies for obesity, heart disease, hypertension, and cancer. See AlsoPSI Structural Biology Database Linked pages of related receptors (co-featured in BAMBED):
Proteopedia ResourcesButler University Proteopedia Pages 3D structures of glucagon receptorUpdated on 12-March-2023 5ee7 - hGCGR + antagonist - human 7s15 - hGCGR + agonist
| ||||||||||||
Student Contributors
Steven Bennett
Sydney Caskey
Alexis Coulis
Olivia Murfield
Allie Paton
Dean Williams
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Karsten Theis, R. Jeremy Johnson, Angel Herraez, Joel L. Sussman
